# US 2026/0248846 A1 · Treatment of Myopic Progression

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248846 A1
- Document ID: US20260248846A1
- Status: Published application
- Kind: A1
- Application number: 19/534,077
- Filed: 2026-02-09
- Published: 2026-08-27
- Earliest claimed: 2018-01-05
- Assignees: University of Utah Research Foundation
- Applicants: University of Utah Research Foundation
- Inventors: Randon Michael Burr; Balamurali K. Ambati; Sarah A. Molokhia
- Web page: https://patentgrep.com/patent/US20260248846A1

## CPC

- A61K 33/34: Copper; Compounds thereof
- A61K 9/0051: {Ocular inserts or implants}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 27/10: for accommodation disorders, e.g. myopia
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

An ophthalmic composition or dosage form can include a therapeutically effective amount of a copper-containing agent that is sufficient to increase corneal lysyl oxidase activity in an eye of a subject in an amount sufficient to treat myopic progression and a pharmaceutically acceptable carrier. The composition or dosage form can be used to treat or prevent progression of myopia by administering a therapeutically effective amount of the composition to an eye of a subject during a treatment period.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A method of increasing corneal biomechanical strength in a myopic eye, comprising:
administering to the myopic eye an ophthalmic composition comprising:
a copper-containing agent; and
a pharmaceutically acceptable carrier,
wherein administration of the ophthalmic composition reduces corneal radial strain relative to an untreated cornea.

### Claim 23 (depends on 22)

The method of claim 22, wherein the copper-containing agent comprises copper sulfate or copper sulfate pentahydrate.

### Claim 24 (depends on 22)

The method of claim 22, wherein administration increases lysyl oxidase activity in corneal tissue.

### Claim 25 (depends on 22)

The method of claim 22, wherein administration increases collagen crosslink density in the cornea.

### Claim 26 (depends on 22)

The method of claim 22, wherein the ophthalmic composition is administered as a topical ophthalmic drop.

### Claim 27 (depends on 22)

The method of claim 22, wherein the ophthalmic composition is administered from one to four times per day.

### Claim 28 (depends on 22)

The method of claim 22, wherein the ophthalmic composition decreases corneal radial strain by at least about 10% relative to baseline.

### Claim 29

A method of remodeling a myopic cornea, comprising:
administering to an eye of a subject an ophthalmic composition comprising:
a copper-containing agent; and
a pharmaceutically acceptable carrier,
wherein administration of the ophthalmic composition decreases corneal diopter relative to baseline.

### Claim 30 (depends on 29)

The method of claim 29, wherein administration induces corneal flattening.

### Claim 31 (depends on 29)

The method of claim 29, wherein the copper-containing agent comprises copper sulfate pentahydrate.

### Claim 32 (depends on 29)

The method of claim 29, wherein the ophthalmic composition is administered topically to the corneal surface.

### Claim 33 (depends on 29)

The method of claim 29, wherein administration increases corneal stiffness relative to baseline.

### Claim 34 (depends on 29)

The method of claim 29, wherein the ophthalmic composition is administered for a treatment period of at least one month.

### Claim 35 (depends on 29)

The method of claim 29, wherein administration decreases corneal diopter by an amount comparable to laser crosslinking.

### Claim 36

A method of increasing collagen crosslink density in a cornea of a myopic eye, comprising:
administering to the eye an ophthalmic composition comprising:
a copper-containing agent; and
a pharmaceutically acceptable carrier,
wherein administration increases lysinonorleucine (LNL) crosslink density in the cornea relative to an untreated cornea.

### Claim 37 (depends on 36)

The method of claim 36, wherein administration increases lysyl oxidase activity in corneal tissue.

### Claim 38 (depends on 36)

The method of claim 36, wherein the copper-containing agent comprises copper sulfate pentahydrate.

### Claim 39 (depends on 36)

The method of claim 36, wherein the ophthalmic composition is administered as a topical eye drop.

### Claim 40 (depends on 36)

The method of claim 36, wherein administration increases corneal biomechanical strength.

### Claim 41 (depends on 36)

The method of claim 36, wherein the ophthalmic composition further comprises a tonicity agent and a pH adjuster.

### Claim 42 (depends on 36)

The method of claim 36, wherein administration increases corneal collagen crosslinking without inducing corneal haze.
